Analysis
Vera Health raised a $28.5 million Series A led by Threshold Ventures, with Mantis VC and SV Angel joining and existing investors Y Combinator and Gradient also increasing their stakes, the company announced on October 27. The round brings Vera Health's total funding to $32 million.
## What Vera Health does Vera Health describes itself as "a clinical AI search engine that reasons like a clinician." Founded in 2024 at Y Combinator by MIT graduates Taieb Bennani and Maxime Allouch, both sons of physicians, the San Francisco company built a tool that searches more than 60 million peer-reviewed publications, clinical guidelines and drug labels, color-coding each claim by strength of evidence. Vera has a formal partnership with the American College of Emergency Physicians to integrate ACEP clinical policies directly into its search results, and its "Vera Spaces" feature lets health systems layer in their own internal protocols. The product is free for licensed clinicians and trainees; the company says it never trains its models on clinicians' questions and holds HIPAA, GDPR and SOC 2 Type II compliance.
## Vera Health's funding history This $28.5 million Series A brings Vera Health's total disclosed funding to $32 million, per the company's own announcement. The release does not break out the size or lead investors of the company's earlier funding, and the jump reflects usage growth rather than a product pivot: Vera's core clinical-search product has stayed consistent since launch while its user base scaled into the hundreds of thousands.
“## Vera Health's funding history This $28.5 million Series A brings Vera Health's total disclosed funding to $32 million, per the company's own announcement.”
## Who invested in Vera Health Threshold Ventures led the new round. Mantis VC and SV Angel joined as new investors, while Y Combinator and Gradient -- both already on Vera's cap table -- put in additional capital. Gradient partner Andrew Brackin is quoted in the announcement, though the release does not break out how much each investor contributed.
## Clinical AI market and competitors Vera Health's growth claims are striking relative to named rivals: the company says it has been the most-downloaded clinical app worldwide on both the App Store and Google Play every month since June 2026, and that September downloads exceeded OpenEvidence and Doximity combined, citing Appark data. More than 800,000 clinicians across 190 countries now use Vera, including roughly 1 in 4 physicians in Spain and Italy and 1 in 7 in France -- adoption the company attributes mostly to word of mouth rather than paid acquisition. A separate company-published benchmark report claims 97.5% accuracy on USMLE questions, ahead of the rival models cited in that same analysis. The broader AI-in-healthcare funding wave tracked in Pulse's funding tracker has produced several well-funded clinical-search rivals, and Vera's free pricing model is both its growth engine and its biggest open question.
## The monetization gap Vera Health has not disclosed a monetization plan, and the company's download and user-adoption figures come from its own press release rather than independent app-store data. A free product with no stated revenue model carries real risk heading into a Series A that values rapid clinician adoption over near-term unit economics -- the next round will likely hinge on whether Vera can convert hospital-system "Vera Spaces" deployments into actual paid contracts rather than free usage at scale.